BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 25576920)

  • 1. mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.
    Beagle BR; Nguyen DM; Mallya S; Tang SS; Lu M; Zeng Z; Konopleva M; Vo TT; Fruman DA
    Oncotarget; 2015 Feb; 6(4):2088-100. PubMed ID: 25576920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
    Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
    Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p21(WAF1) modulates drug-induced apoptosis and cell cycle arrest in B-cell precursor acute lymphoblastic leukemia.
    Davies C; Hogarth LA; Mackenzie KL; Hall AG; Lock RB
    Cell Cycle; 2015; 14(22):3602-12. PubMed ID: 26506264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors reduce WB-F344 oval cell viability and migration capability by suppressing AKT/mTOR signaling in vitro.
    Zhang P; Zhu X; Wu Y; Hu R; Li D; Du J; Jiao X; He X
    Arch Biochem Biophys; 2016 Jan; 590():1-9. PubMed ID: 26558695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
    Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
    J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
    Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
    Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
    Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
    Patel RP; Thomas JR; Curt KM; Fitzsimmons CM; Batista PJ; Bates SE; Gottesman MM; Robey RW
    Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):16. PubMed ID: 34533562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
    Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
    Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
    Haydn T; Metzger E; Schuele R; Fulda S
    Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
    Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
    Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of class I histone deacetylases blunts cardiac hypertrophy through TSC2-dependent mTOR repression.
    Morales CR; Li DL; Pedrozo Z; May HI; Jiang N; Kyrychenko V; Cho GW; Kim SY; Wang ZV; Rotter D; Rothermel BA; Schneider JW; Lavandero S; Gillette TG; Hill JA
    Sci Signal; 2016 Apr; 9(422):ra34. PubMed ID: 27048565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aurora-B and HDAC synergistically regulate survival and proliferation of lymphoma cell via AKT, mTOR and Notch pathways.
    Wang C; Chen J; Cao W; Sun L; Sun H; Liu Y
    Eur J Pharmacol; 2016 May; 779():1-7. PubMed ID: 26638998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.
    Davies C; Hogarth LA; Dietrich PA; Bachmann PS; Mackenzie KL; Hall AG; Lock RB
    J Biol Chem; 2011 Oct; 286(43):37639-50. PubMed ID: 21903579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation.
    Sun DF; Zhang YJ; Tian XQ; Chen YX; Fang JY
    Cell Biol Int; 2014 Jan; 38(1):50-63. PubMed ID: 24030871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
    Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
    Quan P; Moinfar F; Kufferath I; Absenger M; Kueznik T; Denk H; Zatloukal K; Haybaeck J
    Anticancer Res; 2014 Jun; 34(6):2883-97. PubMed ID: 24922651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells.
    Morgan SS; Cranmer LD
    BMC Res Notes; 2014 Nov; 7():812. PubMed ID: 25406429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.
    Stubbs MC; Kim W; Bariteau M; Davis T; Vempati S; Minehart J; Witkin M; Qi J; Krivtsov AV; Bradner JE; Kung AL; Armstrong SA
    Clin Cancer Res; 2015 May; 21(10):2348-58. PubMed ID: 25688158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.